Package(a):
VIALS: 1 x 10 ml. Dosage(a):
Single-dose administration only. See prescribing information for full details. Prescribing Restrictions:
Package(b):
VIALS: 1 x 50 ml. Dosage(b):
Single-dose administration only. See prescribing information for full details. Prescribing Restrictions:
Indications:
Palliative in addition to other modalities in treating metastatic testicular and ovarian cancer, advanced bladder cancer. Contra-Indications:
Hypersensitivity, pre-existing renal impairment, myelosuppressed and patients with hearing impairment. See prescribing information for full details. Special Precautions:
The serum creatinine, BUN and creatinine clearance should be measured prior to initiating therapy and prior to each subsequent course. Use in pregnancy. Careful audiometry monitoring should be performed prior to initiation of therapy and prior to subsequent doses. Peripheral blood counts should be monitored weekly. Therapy should be discontinued when neurological symptoms are first observed. See prescribing information for full details. Side Effects:
Nephrotoxicity, electrolyte disturbances, ototoxicity, neuropathies. Myelosuppression occurs in 25-30% of patients treated. Leukopenia and thrombocytopenia are more pronounced at higher doses. Nausea and vomiting, anaphylactic-like reactions, ocular toxicity, hyperuricemia, cardiac abnormalities, elevated SGOT. See prescribing information for full details. Drug Interactions:
Please contact distributing company for full details.
